Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

ymphocytic leukemia.

Genzyme took a number of major steps during the second quarter to create opportunities for growth beyond 2011 by significantly strengthening its pipeline and expanding its global infrastructure:

-- The company secured exclusive worldwide rights to mipomersen, an innovative cholesterol-lowering drug in Phase 3 development that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current therapies.

-- Genzyme also formed a collaboration this month with PTC Therapeutics to develop and commercialize PTC124, a novel oral therapy under development initially for Duchenne muscular dystrophy and cystic fibrosis. The product has broad potential in a range of other inherited disorders.

-- Genzyme continued to enroll patients in two ongoing Phase 3 trials of alemtuzumab for the treatment of multiple sclerosis. Final, three-year efficacy and safety data from the Phase 2 trial comparing alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting multiple sclerosis were presented during the quarter as part of a scientific platform session at the American Academy of Neurology. The company is awaiting publication of these results.

-- Genzyme announced plans for a research and development center in China and also began building a commercial organization in India, initiatives that reflect the company's commitment to establishing a long-term presence in both countries.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its 2008 earnings guidance; its expectations for approval of Myozyme produced at the 2000L and 4000L-scale capacities, the timing thereof and its assessment of product supply; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD and Clolar for adult AML, the ti
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (N...h Circuit Court of Appeals reversed a U.S. Distric... to pursue all of its claims against The Lash Grou... trial. CTI filed a complaint against The Lash Gr...tant for CTI,s product TRISENOX, in 2007 seeking $...
(Date:11/19/2009)...e/ -- Danish Prince Joachim inaugurated the DONG E...ndborg, Denmark, on Wednesday, November 18. The fa... generation ethanol demonstration biorefineries. G...t,s innovative process for converting straw to fue...to market with commercial enzymes for converting c...
(Date:11/19/2009)...-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), a...er to its shareholders, discussing the Company,s a...aceuticals Holdings, Inc. (CHBP), an integrated bi...ublic of China. The merger gives NeoStem a control.... Ltd., CHBP,s primary operating subsidiary and a ...
(Date:11/19/2009).../ - Aegera Therapeutics Inc. announced today the d...B study of AEG35156, a targeted antisense therapeu... indications. ,, The study, entitled "An Open-L...bitor of Apoptosis (XIAP) Antisense AEG35156 Given...ubicin in AML Following Failure of a Single Standa...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...viduals from academia, government and private indu... of America (WSSA) for their outstanding contribut...s program is designed to recognize individuals fro...ession. Winners are conducting breakthrough resea... their time and energy to the profession in other ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext...today that they have entered into an agreement wit...n their Vendor Network. Under the terms of the agr...generation partner for licensees of the PER.C6(R) ...n King, president of DSM Biologics notes, "The gro...
...5 independent PR agency announced today the additi...ical Group and the Yan Center for Corrective &... diverse roster of clientele. Both medical centers...ent their public relations programs. , , "We are ... have selected 5W PR as their agency of record," s...
Other Biology Technology:Weed Science Society of America Announces Winners in Annual Scientific Awards Program 2Weed Science Society of America Announces Winners in Annual Scientific Awards Program 3Weed Science Society of America Announces Winners in Annual Scientific Awards Program 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations 2
(Date:11/23/2009)...s like frogs and toads have existed for 360 millio...t a new aquatic fungus is threatening to make many...ovember issue of Microbiology Today . , The fu...ound to be associated with waves of amphibian exti...alia in the 1990,s. Bd infects over 350 amphibian ...
(Date:11/23/2009)...ists have revealed how environmental irritants suc...e to cough, in research published today in the Am...dicine . The authors of the study, from Imperial C...ntified the reaction inside the lungs that can tri...ar irritants in the air. They suggest that their f...
(Date:11/23/2009)...ease is available in German . , Of all glob...late in the atmosphere where it contributes to glo...s and terrestrial ecosystems such as forests, gras...ice" of aquatic and terrestrial ecosystems is cons... of reducing climate change. However, new greenhou...
Breaking Biology News(10 mins):Research reveals exactly how coughing is triggered by environmental irritants 2Intensive land management leaves Europe without carbon sinks 2Researchers link inflammatory diseases to increased cardiovascular risk 55912 1Researchers link inflammatory diseases to increased cardiovascular risk 55912 2National Education Association Health Information Network 28NEA HIN 29 and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 55911 1National Education Association Health Information Network 28NEA HIN 29 and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 55911 2National Education Association Health Information Network 28NEA HIN 29 and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 55911 3Express Scripts to Present at Investor Conferences 13781 1Express Scripts to Present at Investor Conferences 13781 2
... most deadly form of skin cancer, can be successfu...with tumor proteins. How these vaccines work and w...s unclear. Pierre Coulie and colleagues now show, ...rnal of Experimental Medicine, that these vaccines...led killer T cells that can attack the tumor. In a...
...arge-scale study to date of the proteins that pack...hes that turn genes on and off. Their findings may...underlying cancer and human development. , The re...n, recipient of a Howard Hughes Medical Institute ... in the Harvard University laboratory of HHMI inve...
...nd error, scientists have coaxed human embryonic s... nervous system pathways that relay messages from ...ings, reported online today (Jan. 30, 2005) in the...he University of Wisconsin-Madison, are important ...tists trying to repair damaged or diseased nervous...
Other Biology News:Man and mouse share genome structures 2Man and mouse share genome structures 3Wisconsin scientists grow critical nerve cells 2Wisconsin scientists grow critical nerve cells 3
Agencourt SPRPlate 384 Magnet Plate from Agencourt Bioscience
SDS-OUT PRECIP. Kit from Pierce Biotechnology, Inc.
Solvent-Detergent Removal Resin from Sigma-Aldrich
Agencourt SPRPlate D - Disc Magnet Plate from Agencourt Bioscience
Biology Products: